Table 1.

Characteristics of patients harboring dual-positive ALK/EGFR alterations

Patient Characteristics	EML4-ALK	Non-EML4-ALK	P-value
Total	11	10
Co-occurrence rate in ALK-rearranged NSCLC	3.06% (11/359)	16.67% (10/60)	p<0.01
Gender			p=0.02
Male	4	9
Female	7	1
Age (year)			p=0.31
Median	53	59.5
Range	42–74	44–81
Histological types
Adenocarcinoma	11	10

Abbreviations: ALK, anaplastic lymphoma kinase; NSCLC, nonsmall cell lung cancer; EML4, echinoderm microtubule-associated protein-like 4.